免疫检查点抑制剂致免疫介导性肝损伤研究进展  

Research progress in immune checkpoint inhibitors‑induced immune‑mediated liver injury

作　　者：张文[1] 王旭升 刘云霞 卢翠翠 Zhang Wen;Wang Xusheng;Liu Yunxia;Lu Cuicui(Department of Pharmacy,Shandong Provincial Hospital Affiliated to Shandong University,Jinan 250021,China;Department of Pharmacy,Shandong First Medical University,Shandong Province,Taian 271016,China)

机构地区：[1]山东大学附属省立医院药学部,济南250021 [2]山东第一医科大学药学院,泰安271016

出　　处：《药物不良反应杂志》2021年第1期30-34,共5页Adverse Drug Reactions Journal

基　　金：科技部国家重点研发计划(2020YFC2008920)。

摘　　要：免疫检查点抑制剂(ICI)所致免疫介导性肝损伤(IMH)是特殊类型的药物性肝损伤,其危险因素包括联合使用不同种类ICI、合并疾病和发热等。多数IMH患者无临床症状,主要表现为血清肝酶水平异常。停止或推迟使用ICI以及进行免疫抑制治疗对IMH患者至关重要,免疫抑制治疗通常使用糖皮质激素,也可加用他克莫司、吗替霉酚酸酯等免疫抑制剂。Immune checkpoint inhibitors(ICIs)‑associated immune‑mediated hepatitis(IMH)is a special type of drug‑induced liver injury.The risk factors of IMH include combination of different types of ICIs,comorbidities,fever,etc.Most patients with IMH are asymptomatic,but laboratory tests show mainly abnormal levels of serum transaminase.It is crucial for patients with IMH to stop or delay the use of ICIs and receive immunosuppressive therapy.The immunosuppressive therapy for IMH usually includes glucocorti‑coids,and the immunosuppressive agents such as tacrolimus,mycophenolate mofetil,etc.can also be added.

关 键 词：化学和药物性肝损伤 糖皮质激素 免疫抑制剂 免疫检查点抑制剂 

分 类 号：R969.3[医药卫生—药理学]